Search

Home > New FDA Approvals > 020 - Priority review for Abbvie’s elagolix, a GnRH antagonist for the management of endometriosis with associated pain; Eagle Pharma gets tentative FDA approval for a version of pemetrexed; Lupin receives FDA approval for generic Lodosyn® tablets
Podcast: New FDA Approvals
Episode:

020 - Priority review for Abbvie’s elagolix, a GnRH antagonist for the management of endometriosis with associated pain; Eagle Pharma gets tentative FDA approval for a version of pemetrexed; Lupin receives FDA approval for generic Lodosyn® tablets
Category: Science & Medicine
Duration: 0
Publish Date: 2017-10-30 06:00:00
Description:

October 30, 2017

0:31 The FDA has granted priority review for elagolix, an investigational, orally administered gonadotropin-releasing hormone (GnRH) antagonist, being investigated for the management of endometriosis with associated pain.

https://news.abbvie.com/news/press-releases/abbvie-receives-us-fda-priority-review-for-investigational-oral-treatment-elagolix-for-management-endometriosis-with-associated-pain.htm

2:44 Eagle Pharma gets tentative FDA approval for Lilly's Alimta version

https://www.reuters.com/article/us-eagle-pharms-fda/eagle-pharma-gets-tentative-fda-approval-for-lillys-alimta-version-idUSKBN1CW2RI

http://investor.eagleus.com/press-release/eagle-pharmaceuticals-receives-tentative-fda-approval-pemfexy-pemetrexed-injection-rea

4:21 Lupin receives FDA approval for generic Lodosyn® tablets

http://www.lupin.com/lupin-receives-fda-approval-for-generic-lodosyn-tablets.php
Total Play: 0